RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
Sign Up to like & getrecommendations! Published in 2023 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001500
Abstract: Reactive oxygen species (ROS) levels are elevated after acquisition of resistance to v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors including dabrafenib and MEK inhibitors such as trametinib in BRAF-mutant melanoma. To circumvent toxicity… read more here.
Keywords: tdr; ridr 103; braf; inhibitor ... See more keywords